News

Home Depot disappoints, Novo Nordisk's GLP-1 updates, an AI warning and more in Morning Squawk

Home Depot kicked off this week's string of retailer earnings reports. Novo Nordisk provided two major updates on its ...

Eli Lilly Vs. Novo Nordisk: Correction Overly Done - GLP-1 Market Leadership/ Robust Pipelines Ahead

Novo Nordisk's (NVO) corrections amid AI market rotation might be an opportunity, due to GLP-1 market leadership & balanced ...
Fierce Pharma13d

Novo's outgoing CEO prepares to hand off business as sales threats from Lilly, GLP-1 compounders persist

On the one hand, the company is struggling to stay competitive with its chief rival Eli Lilly, and on the other, compounders ...

GoodRx CEO discusses GLP-1 deal with Novo Nordisk: What to know

GoodRx (GDRX) stock is skyrocketing after the company struck a deal with Novo Nordisk (NVO) to offer lower prices on GLP-1 ...

GLP-1 War: A Look At The Epic Pipeline Battle Between Novo Nordisk And Eli Lilly

Novo Nordisk remains a strong buy despite share price dip, thanks to its robust drug pipeline, massive market potential, and compelling long-term ...

One in four US adults with diabetes used a GLP-1 drug last year, survey finds

More than one in four U.S. adults with diabetes used one of the injectable medicines that target the GLP-1 protein last year, ...

Despite FDA ruling, compounded GLP-1s are still giving Novo and Lilly headaches on the market

When the FDA took Novo Nordisk and Eli Lilly’s GLP-1 medications off of the drug shortage list, the move should have been a ...

Novo Nordisk: The Falling Knife That Keeps Giving

Novo Nordisk's growth in diabetes and obesity care makes it a strong buy. Click here for a full investment analysis of NVO ...